Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease
- PMID: 26033496
- PMCID: PMC11113985
- DOI: 10.1007/s00018-015-1937-8
Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease
Abstract
Glutamate is the predominant excitatory neurotransmitter in the central nervous system. Excitatory amino acid transporter 2 (EAAT2) is primarily responsible for clearance of extracellular glutamate to prevent neuronal excitotoxicity and hyperexcitability. EAAT2 plays a critical role in regulation of synaptic activity and plasticity. In addition, EAAT2 has been implicated in the pathogenesis of many central nervous system disorders. In this review, we summarize current understanding of EAAT2, including structure, pharmacology, physiology, and functions, as well as disease relevancy, such as in stroke, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, major depressive disorder, and addiction. A large number of studies have demonstrated that up-regulation of EAAT2 protein provides significant beneficial effects in many disease models suggesting EAAT2 activation is a promising therapeutic approach. Several EAAT2 activators have been identified. Further understanding of EAAT2 regulatory mechanisms could improve development of drug-like compounds that spatiotemporally regulate EAAT2.
Figures
Similar articles
-
Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.Future Med Chem. 2012 Sep;4(13):1689-700. doi: 10.4155/fmc.12.122. Future Med Chem. 2012. PMID: 22924507 Free PMC article.
-
Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalization.Glia. 2014 Aug;62(8):1241-53. doi: 10.1002/glia.22677. Epub 2014 Apr 21. Glia. 2014. PMID: 24753081 Free PMC article.
-
GLT-1 transporter: an effective pharmacological target for various neurological disorders.Pharmacol Biochem Behav. 2014 Dec;127:70-81. doi: 10.1016/j.pbb.2014.10.001. Epub 2014 Oct 13. Pharmacol Biochem Behav. 2014. PMID: 25312503 Review.
-
Current approaches to enhance glutamate transporter function and expression.J Neurochem. 2015 Sep;134(6):982-1007. doi: 10.1111/jnc.13200. Epub 2015 Aug 14. J Neurochem. 2015. PMID: 26096891 Review.
-
The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.Neuropharmacology. 2019 Dec 15;161:107559. doi: 10.1016/j.neuropharm.2019.03.002. Epub 2019 Mar 6. Neuropharmacology. 2019. PMID: 30851309 Free PMC article. Review.
Cited by
-
Astrocytic neuroligin 3 regulates social memory and synaptic plasticity through adenosine signaling in male mice.Nat Commun. 2024 Oct 5;15(1):8639. doi: 10.1038/s41467-024-52974-3. Nat Commun. 2024. PMID: 39366972 Free PMC article.
-
Inhibition of p38 MAPK Signaling Regulates the Expression of EAAT2 in the Brains of Epileptic Rats.Front Neurol. 2018 Oct 29;9:925. doi: 10.3389/fneur.2018.00925. eCollection 2018. Front Neurol. 2018. PMID: 30429824 Free PMC article.
-
The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking?Biomolecules. 2023 Mar 1;13(3):453. doi: 10.3390/biom13030453. Biomolecules. 2023. PMID: 36979388 Free PMC article. Review.
-
Manganese-induced reactive oxygen species activate IκB kinase to upregulate YY1 and impair glutamate transporter EAAT2 function in human astrocytes in vitro.Neurotoxicology. 2021 Sep;86:94-103. doi: 10.1016/j.neuro.2021.07.004. Epub 2021 Jul 24. Neurotoxicology. 2021. PMID: 34310962 Free PMC article.
-
Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse.Int J Neuropsychopharmacol. 2017 Oct 1;20(10):797-812. doi: 10.1093/ijnp/pyx050. Int J Neuropsychopharmacol. 2017. PMID: 28605494 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical